Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

3.935 +0.025 (+0.64%)
Streaming Delayed Price Updated: 12:54 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bioxcel Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Are BioXcel Therapeutics Shares Plummeting Today
BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are tumbling after the company released topline results for TRANQUILITY II, a Phase 3 trial of BXCL501 for the acute treatment of  
Via Benzinga
Dow Rises Over 100 Points; US GDP Grows 2% In Q1
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.37% to 33,977.04 while the NASDAQ rose... 
Via Benzinga
FREY Stock Price Prediction: Is Freyr Battery Really Worth $13?
Freyr Battery (FREY) stock is on the move Thursday with heavy trading following positive coverage from analysts at Morgan Stanley. 
Via InvestorPlace
Why Is Cormedix (CRMD) Stock Down 23% Today?
Cormedix (CRMD) stock is falling hard on Thursday with heavy trading after the company priced a public offering of its shares. 
Via InvestorPlace
Goldman Sachs Maintains Neutral Rating for BioXcel Therapeutics: Here's What You Need To Know
Via Benzinga
Where BioXcel Therapeutics Stands With Analysts
Via Benzinga
Why Shares of BioXcel Therapeutics Are Dropping Thursday
A trial for one of the company's therapies didn't meet its primary endpoint. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?
BioXcel Therapeutics (BTAI) stock is taking a beating on Thursday after the company released its latest clinical trial data. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today! 
Via InvestorPlace
BioXcel CEO Vimal Mehta Says This Alzheimer's News Is A 'Huge Win For Society'
The company hopes to soon gain approval to treat patients with agitation due to Alzheimer's disease. 
Via Investor's Business Daily
Looking Into BioXcel Therapeutics's Return On Capital Employed
Via Benzinga
The Latest Analyst Ratings for BioXcel Therapeutics
Via Benzinga
Why BioXcel Therapeutics Stock Marched Higher Today
The biotech's Q1 earnings report set the stage for a flurry of important clinical updates in the coming months. 
Via The Motley Fool
BioXcel Therapeutics's Earnings Outlook
Via Benzinga
3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally
If you can’t stand a dull day at the trading desk, these short-squeeze stocks to buy could spike your blood pressure and your portfolio. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 211.6% to $6.86 after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR. 
Via Benzinga
6 Analysts Have This to Say About BioXcel Therapeutics
Via Benzinga
BioXcel Therapeutics Stock Tumbles: Company Releases Mixed Results From Lower Dose Igalmi Study In Bipolar/Schizophrenia Associated Agitation
Via Benzinga
BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain
The company is hoping to double its market opportunity. But that looks less certain. 
Via Investor's Business Daily
BioXcel Therapeutics Reports Encouraging Phase 1b Results For Innovative Depression Treatment
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced topline data from its Phase 1b multiple ascending dose (MAD) trial of BXCL501 (dexmedetomidine) sublingual film, for agitation associated with... 
Via Benzinga
Why These 3 Nasdaq Stocks Were Glowing Green This Week
These three biopharmaceutical stocks rocketed higher this week. 
Via The Motley Fool
BioXcel Earnings Miss Q1 Estimates Due To Higher Costs, Expects Uptick In Revenues
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported first-quarter FY23 revenues of $206,000,  
Via Benzinga
Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite.
Axsome shares are nearing a breakout point. But BioXcel crumbled on its report. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEO
This company is hoping to execute for a second time on its moonshot goal. 
Via Investor's Business Daily
Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Tuesday
Morgan Stanley boosted the price target for HubSpot, Inc. (NYSE: HUBS) from $447 to $466. Morgan Stanley analyst Keith Weiss maintained an Overweight rating. HubSpot shares fell 1.9% to close at... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.